KLH

Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX
VENTURE: KLH) announced today the appointment of Gregory T. Baxter, Ph.D. and
Charles V. Olson, D.Sc. to the Company's Scientific Advisory Board (SAB). They
will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse, Ph.D.
and Andrew Saxon, M.D. on the SAB. Stellar's SAB is composed of eminent
scientists and physicians representing a range of disciplines including
immunology, molecular biology and biochemistry. The SAB will be an ongoing
resource to provide Stellar's management with counsel and guidance pertaining to
the research, development, and clinical application of Stellar's KLH technology.


Dr. Gregory Baxter, a member of Stellar's Board of Directors since August 2012,
is a Senior Scientist in the Department of Clinical Drug Development for CCS
Associates, Inc. He also serves as Adjunct Associate Professor at Cornell
University in the College of Chemical Engineering and on the Founders Board of
Stanford University's StartX Med Program. Dr. Baxter's background spans both
science and business arenas including Program Director for the National Science
Foundation (NSF) Division of Industrial Innovation and Partnerships; Founder and
CSO of Hurel Corporation; Founder and CEO of Aegen Biosciences; and Research
Scientists for Molecular Devices Corporation. Dr. Baxter received his Ph.D. in
Biochemistry/Molecular Biology from the University of California, Santa Barbara.


"It's been gratifying to be a part of Stellar's corporate achievements this past
year and I look forward to contributing on the Company's research front and in
the advancement of its C. diff immunotherapy program," said Dr. Baxter.


Dr. Charles Olson is a biotechnology industry professional with broad scientific
and operational experience, and specialization in manufacturing operations and
process development. Dr. Olson currently serves as Vice President of CMC and
Technical Operations for NGM Biopharmaceuticals and Vice President of Protein
Sciences for Anthera Pharmacetuicals. His background includes the positions of
Senior VP of Product Development and Operations for Nexbio Inc.; VP of Hayward
Operations for Cell Genesys; Senior Director of Manufacturing, Facilities and
Process Development for Biomarin Pharmaceuticals; and Director of Manufacturing
Sciences for Onyx Pharmaceuticals. Dr. Olson received his D.Sc. in Biochemistry
from Hawthorne University.


"This is an exciting time for Stellar with its many promising commercial
opportunities that the Company has in its sights," said Dr. Olson. "I am excited
to join a team with such a strong technology position, and I look forward to
being a part of their success."


Frank Oakes, Stellar's president and CEO, said, "We are delighted to have both
of these biotechnology experts available to our internal teams and to advise our
Board of Directors as we advance corporate objectives and deliver on key
research and operational goals."


To receive timely updates of Stellar Biotechnologies news and events please
register for our email alert, by signing up at:
http://ir.stellarbiotechnologies.com/email-alerts


About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in
sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important
immune-stimulating protein used in wide-ranging therapeutic and diagnostic
markets. KLH is both an active pharmaceutical ingredient (API) in many new
immunotherapies (targeting cancer, infectious diseases, and immune disorders) as
well as a finished product for measuring immune status. Stellar Biotechnologies
is unique in its proprietary methods, facilities, and KLH technology. We are
committed to meeting the growing demand for commercial-scale supplies of GMP
grade KLH, ensuring environmentally sound KLH production, and developing
KLH-based active immunotherapies.


Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements may be
identified by the use of words such as "anticipate," "believe," "plan,"
"estimate," "expect," "intend," "may," "will," "would," "could," "should,"
"might," "potential," or "continue" and variations or similar expressions.
Readers should not unduly rely on these forward-looking statements, which are
not a guarantee of future performance. There can be no assurance that
forward-looking statements will prove to be accurate, as all such
forward-looking statements involve known and unknown risks, uncertainties and
other factors which may cause actual results or future events to differ
materially from the forward-looking statements. Such risks include, but may not
be limited to: general economic and business conditions; technology changes;
competition; changes in strategy or development plans; governmental regulations
and the ability or failure to comply with governmental regulations; the timing
of anticipated results; and other factors referenced in the Company's filings
with securities regulators. For a discussion of further risks and uncertainties
related to the Company's business, please refer to the Company's public company
reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange
Commission. All forward-looking statements are made as of the date hereof and
are subject to change. Except as required by law, the Company assumes no
obligation to update such statements. This press release does not constitute an
offer or solicitation of an offer for sale of any securities in any
jurisdiction, including the United States. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the
information contained in this press release.




FOR FURTHER INFORMATION PLEASE CONTACT: 
Frank Oakes
President and CEO
Phone +1 (805) 488-2800
IR@stellarbiotech.com


Mark McPartland
Vice President of Corporate Development and Communications
Phone: +1 (805) 488-2800 ext. 103
markmcp@stellarbiotech.com
www.stellarbiotech.com

Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
From May 2024 to Jun 2024

Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
From Jun 2023 to Jun 2024